

## Correction: *On the mechanism of anti-CD39 immune checkpoint therapy*

---

Allard D, Allard B, Stagg J. On the mechanism of anti-CD39 immune checkpoint therapy. *J Immunother Cancer* 2020;8:e000186. doi: 10.1136/jitc-2019-000186

In this article, there was an error in the formatting of the P2X receptors in the text. This error has since been corrected.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

*J Immunother Cancer* 2020;8:e000186corr1. doi:10.1136/jitc-2019-000186corr1

